Filtered By:
Condition: Bleeding
Procedure: Heart Transplant

This page shows you your search results in order of date.

Order by Relevance | Date

Total 176 results found since Jan 2013.

Colocutaneous Fistula Following Pediatric Bivad Implantation, A Rare but Serious Complication
We present 2 patients who had rare colocutaneous fistulas associated with Berlin Heart EXCOR ® placement.
Source: The Journal of Heart and Lung Transplantation - April 1, 2023 Category: Transplant Surgery Authors: S. Rangu, J. Murray, A. Shiu, E. Martin, T. Nasirov, M. Bruzoni, S. Chen, D. Rosenthal, M. Ma, J. Dykes Tags: (1035) Source Type: research

Impact of Perioperative Sarcopenia and Dysphagia on LVAD Related Complications
Sarcopenia, as defined by decline in muscle quantity/quality, is prevalent in heart failure and associated with high morbidity and mortality. Sarcopenic dysphagia is caused by sarcopenia in the whole body and swallowing-related muscles. We investigated the impact of perioperative sarcopenia and dysphagia on postoperative pneumonia (PNA), stroke, gastrointestinal bleeding (GIB) and 30-d readmission after LVAD.
Source: The Journal of Heart and Lung Transplantation - April 1, 2023 Category: Transplant Surgery Authors: M. Nishikawa, M.R. Carey, A. Ladanyi, G.M. Mondellini, A. Pinsino, K. Antler, E. Goldberg, J. Hastie, K. Clerkin, G.T. Sayer, N. Uriel, K. Takeda, P.C. Colombo, M. Yuzefpolskaya Tags: (765) Source Type: research

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Identifying patients at risk: multi ‐centre comparison of HeartMate 3 and HeartWare left ventricular assist devices
ConclusionsHM3 patients have a significantly better survival and a lower incidence of ischaemic strokes and pump thrombosis than HVAD patients. This survival difference persisted after 2  years of implantation. Additional research using post-operative variables is warranted to identify which HVAD patients need an upgrade to HM3 or expedited transplantation.
Source: ESC Heart Failure - February 17, 2023 Category: Cardiology Authors: Lieke Numan, Daniel Zimpfer, Osnat Itzhaki Ben Zadok, Emmeke Aarts, Michiel Morshuis, Sabina P.W. Guenther, Julia Riebandt, Dominik Wiedemann, Faiz Z. Ramjankhan, Anne ‐Marie Oppelaar, Tuvia Ben‐Gal, Binyamin Ben‐Avraham, Folkert W. Asse Tags: Original Article Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Sixth Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report
CONCLUSIONS: This Sixth Pedimacs Report demonstrates the continued evolution of the pediatric field. The complexity of cardiac physiologies and anatomical constraint mandates the need for multiple types of devices utilized (PC, PP, IC). Detailed analyses of each device type in this report provide valuable information to further advance the care of this challenging and vulnerable population.PMID:36402175 | DOI:10.1016/j.athoracsur.2022.10.042
Source: The Annals of Thoracic Surgery - November 19, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Iki Adachi David M Peng Seth A Hollander Kathleen E Simpson Ryan R Davies Jeffrey P Jacobs Christina J VanderPluym Francis Fynn-Thompson Dennis A Wells Sabrina P Law Shahnawaz Amdani Ryan Cantor Devin Koehl James K Kirklin David L S Morales Joseph W Rossa Source Type: research

Clinical outcomes of grafted vs. percutaneous axillary intra-aortic balloon pump support as a bridge to transplantation: a propensity score-matched analysis
ConclusionIn the propensity score matching analysis, there were not any significant differences between the two groups in IABP-related complications, in-hospital mortality, and late survival. The percutaneous technique provided a shorter operation time and less requirement of transfusion and re-exploration for bleeding compared to the grafted technique. The percutaneous technique might be favorable when feasible.
Source: Heart and Vessels - November 1, 2022 Category: Cardiology Source Type: research

Contemporary Mechanical Circulatory Support With Continuous-Flow Biventricular Assist Devices: A Systematic Review
As the incidence of heart failure increases, so too has that of biventricular failure. While transplantation remains the gold standard therapy for end-stage heart failure, the limited organ supply has increased the need for durable mechanical circulatory support. We therefore sought to conduct a systematic review of continuous-flow ventricular assist devices in a biventricular configuration (CF-BiVAD). An electronic search of PubMed and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases was performed using the keyword “BIVAD.” Studies were reviewed to identify discrete variables, including impl...
Source: Cardiology in Review - June 10, 2022 Category: Cardiology Tags: Review Articles Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Comparing short ‐term/long‐term outcomes of heart transplants that occur inside and outside of normal working hours
ConclusionThere was no significant difference in clinical outcomes between heart transplants taking place inside or outside of working hours. A high quality of care can be provided for heart transplant patients even during after hours.
Source: ESC Heart Failure - April 23, 2022 Category: Cardiology Authors: Hidefumi Nishida, Christopher Salerno, David Onsager, Tae Song, Ann Nguyen, Jonathan Grinstein, Bow Chung, Bryan Smith, Sara Kalantari, Nitasha Sarswat, Gene Kim, Sean Pinney, Valluvan Jeevanandam, Takeyoshi Ota Tags: Original Article Source Type: research

Advancements in left ventricular assist devices to prevent pump thrombosis and blood coagulopathy
J Anat. 2022 Apr 20. doi: 10.1111/joa.13675. Online ahead of print.ABSTRACTMechanical circulatory support (MCS) devices, such as left ventricular assist devices (LVADs) are very useful in improving outcomes in patients with advanced-stage heart failure. Despite recent advances in LVAD development, pump thrombosis is one of the most severe adverse events caused by LVADs. The contact of blood with artificial materials of LVAD pumps and cannulas triggers the coagulation cascade. Heat spots, for example, produced by mechanical bearings are often subjected to thrombus build-up when low-flow situations impair washout and thus th...
Source: Journal of Anatomy - April 21, 2022 Category: Anatomy Authors: Grainne Malone Gerges Abdelsayed Fianait Bligh Fatma Al Qattan Saifullah Syed Prateepan Varatharajullu Augustin Msellati Daniela Mwipatayi Maimoona Azhar Andrew Malone Saulat H Fatimi Claire Conway Aamir Hameed Source Type: research